Skip to main content

Table 2 Analysis of the independent Validation Series A risk group predictions generated using the 160-gene prognostic signature

From: Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer

Stage No. Patients Kaplan Meier Analysis (160-gene signature assigned high/low risk categories) Cox Proportional Hazards Regression (160-gene signature assigned high/low risk categories) Receiver Operator Curve analysis (association with 5-year DSS)
Univariate P-value Hazard Ratio (95 % CI) Multivariate P-value Hazard Ratio (95 % CI) P-value AUC (95 % CI)
I & II 264 <0.0001 2.26 (1.46 to 3.50) <0.0001 2.80 (1.83 to 4.28) 0.0004 0.66 (0.59 to 0.71)
I 201 0.0008 2.23 (1.30 to 3.84) <0.0001 3.00 (1.78 to 5.08) 0.0002 0.68 (0.61 to 0.75)
IA 93 0.18 1.76 (0.70 to 4.47) 0.045 2.65 (1.029 to 6.83) 0.019 0.69 (0.59 to 0.78)
IB 97 0.0008 2.79 (1.38 to 5.64) <0.0001 5.44 (2.48 to 11.97) <0.0001 0.75 (0.65 to 0.83)
II 63 0.048 2.00 (0.98 to 4.14) 0.042 2.20 (1.034 to 4.69) 0.56 0.56 (0.42 to 0.70)
IIA 13 0.0097 5.57(1.59 to 19.59) 0.048 28.21 (1.048 to 759.30) 1.0 0.50 (0.17 to 0.83)
IIB 44 0.42 1.47 (0.56 to 3.83) 0.48 1.44 (0.52 to 4.027) 0.57 0.57 (0.40 to 0.58)
  1. Cox Proportional Regression analysis included stage*, microarray type, gender, treatment and age. *where possible, eg.stage IA vs. IB were in the analysis of all Stage I patients.